CLINICAL TRIAL SUMMARY

MDACC Study No:2007-0818 (clinicaltrials.gov NCT No: NCT00756470)
Title:A Phase II Study of Neoadjuvant Lapatinib plus Chemotherapy (Sequential FEC75 and Paclitaxel) in Women with Inflammatory Breast Cancer whose Tumors Overexpress ErbB2 (Her2/neu)
Principal Investigator:Ricardo Alvarez
Treatment Agent:5-Fluorouracil; Cyclophosphamide; Epirubicin; Lapatinib; Paclitaxel
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn how well lapatinib taken
alone, followed by taking lapatinib with paclitaxel, and then taking lapatinib
with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC75) works to help to
control IBC. The safety of this drug combination will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Breast
Phase of Study:Phase II
Treatment Agents:5-Fluorouracil
Cyclophosphamide
Epirubicin
Lapatinib
Paclitaxel
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:GlaxoSmithKline
Return Visit:After pre-dose run-in phase, once every 3 weeks
Home Care:N/A


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Ricardo Alvarez
Dept:Breast Medical Oncology
For Clinical Trial Enrollment:713-792-2817
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults